Malignant Glioma: Novel Therapeutic Strategies
Deadline for manuscript submissions: closed (30 January 2022) | Viewed by 23247
Interests: glioblastoma; combination therapy; apoptosis; temozolomide
Interests: tumor cell metabolism; intelligent intracerebral implants; drug repurposing
Special Issues, Collections and Topics in MDPI journals
Malignant gliomas are a group of hard-to-treat brain tumors. Glioblastoma is among the most aggressive forms of these primary brain tumors, and is associated for most patients with an overall survival of less than 18 months. This is despite an intensive treatment regime of maximal safe tumor resection, followed by radiotherapy and treatment with the alkylating agent temozolomide.
While novel treatment strategies are obviously in dire need, glioma come with a unique set of difficulties that need to be overcome, such as the blood–brain barrier, which prevents access of many drugs to the tumor, or at least to the invading cells that have left the tumor bulk. Furthermore, glioblastoma cells have invariably spread throughout the brain upon presentation, necessitating a treatment approach that is brain systemic.
With these particular features of brain tumors, it is difficult to successfully implement strategies that have shown promise in other cancer entities. However, in recent years novel promising treatment approaches have been put forward that take the specific features of gliomas into account.
The journal Pharmaceuticals invites both reviews and original articles shedding light on the challenges and opportunities specific to glioma. Topics include drug repurposing, the roles of the immune system and the tumor metabolism, as well as improving our understanding of already implemented strategies. The collection of manuscripts will be published as a Special Issue of the journal.
Dr. Mike-Andrew Westhoff
Prof. Georg Karpel-Massler
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cell death
- drug repurposing
- Cancer Translational Biomarkers and Targeted Therapies in Pharmaceuticals (16 articles)
- Clinical Development of Cancer Treatment in Pharmaceuticals (5 articles)
- Anticancer Drugs in Pharmaceuticals (10 articles)
- Treatment Options and Therapeutics for Non-small Cell Lung Cancer in Pharmaceuticals (9 articles)
- New Therapies for Hepatocellular Carcinoma in Pharmaceuticals (6 articles)